Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H
Lancet. 2000 Nov 25;356(9244):1821-2. doi: 10.1016/s0140-6736(00)03239-6.
Four patients with Crohn's disease and spondyloarthropathy were treated with infliximab for treatment-resistant gut inflammation. A substantial improvement in gastrointestinal signs and symptoms was noted, which was accompanied by a rapid reduction in C-reactive protein concentrations. Moreover, all four patients had a significant improvement of axial manifestations and/or peripheral arthritis, related to their spondyloarthropathy. This fast and substantial improvement of the articular manifestations of Crohn's disease after infliximab treatment warrants further investigation of the therapeutic potential of TNF-alpha blockade in other subtypes of spondyloarthropathies.
4例克罗恩病合并脊柱关节病患者接受英夫利昔单抗治疗难治性肠道炎症。观察到胃肠道体征和症状有显著改善，同时C反应蛋白浓度迅速降低。此外，所有4例患者的脊柱关节病相关的轴向表现和/或外周关节炎都有显著改善。英夫利昔单抗治疗后克罗恩病关节表现的这种快速且显著的改善值得进一步研究TNF-α阻断在其他亚型脊柱关节病中的治疗潜力。
